UGT1A1 and Hyperbilirubinemia: It has been reported that many tyrosine kinase inhibitors have lower IC50 values than their clinical steady-state maximum concentrations in UGT1A1 inhibition assays in vitro, in contrast showing a higher incidence of hyperbilirubinemia in vivo experiments.